Treatment options for thalassemia patients with osteoporosis

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 237-243

  Terpos, Evangelos ^a   Voskaridou, Ersi ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

bisphosphonates; osteoporosis; pathogenesis; thalassemia; therapy

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CHORIONIC GONADOTROPIN; CLODRONIC ACID; COLLAGEN TYPE 1; DEFEROXAMINE; ESTROGEN; HEMOGLOBIN; HYDROXYUREA; PAMIDRONIC ACID; PLACEBO; SOMATOMEDIN; VITAMIN D; ZOLEDRONIC ACID;

BONE MARROW DISEASE; CALCIUM INTAKE; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EXERCISE; GASTROINTESTINAL SYMPTOM; GENETIC REGULATION; HEMOGLOBIN BLOOD LEVEL; HEMOSIDEROSIS; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IRON CHELATION; IRON OVERLOAD; LOW DRUG DOSE; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; SEXUAL MATURATION; SMOKING CESSATION; THALASSEMIA; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY;

EID: 77955862472     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05542.x     Document Type: Conference Paper

References (40)

1. Voskaridou, E. & E. Terpos. 2004. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br. J. Haematol. 127: 127-139.
2. Garofalo, F., A. Piga, R. Lala, et al. 1998. Bone metabolism in thalassemia. Ann. N.Y. Acad. Sci. 850: 475-478.
3. Voskaridou, E. & E. Terpos. 2008. Pathogenesis and management of osteoporosis in thalassemia. Pediatr. Endocrinol. Rev. 6(Suppl. 1): 86-93.
4. Hatori,M., J. Sparkman, C.C. Teixeira, et al. 1995. Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia. Calcif. Tissue Int. 57: 229-236.
5. Olivieri, N.F. 1999. The beta-thalassemias. N. Engl. J. Med. 341: 99-109.
6. Lasco, A.,N.Morabito, A. Gaudio, et al. 2001. Effects of hormonal replacement therapy on bone metabolism in young adults with beta- thalassemiamajor. Osteoporos. Int. 12: 570-575.
7. Carmina, E., G. Di Fede, N. Napoli, et al. 2004. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif. Tissue Int. 74: 68-71.
8. World Health Organization. 1994. Assessment of fracture risks and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 843: 1-129.
9. Binkley, N.C., P. Schmeer, R.D.Wasnich & L. Lenchik. 2002. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J. Clin. Densitom. 5(Suppl.): 19-27.
10. Wonke, B.,C. Jensen, J.J.Hanslip, et al. 1998. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J. Pediatr. Endocrinol. Metab. 11(Suppl. 3): 795-801.
11. Uitterlinden, A.G., A.E.Weel,H. Burger, et al. 2001. Interaction between the vitamin D receptor gene and collagen type I alpha 1 gene in susceptibility for fracture. J. Bone Miner. Res. 16: 379-385.
12. Uitterlinden, A.G., H. Burger, C.M. van Duijn, et al. 2000. Adjacent genes, for COL2A1 and the vitamin D receptor, are associated with separate features of radiographic osteoarthritis of the knee. Arthritis Rheum. 43: 1456-1464.
13. Perrotta, S., M.D. Cappellini, F. Bertoldo, et al. 2000. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br. J. Haematol. 111: 461-466.
14. Berkovitch, M., T. Bistritzer, S.D. Milone, et al. 2000. Iron deposition in the anterior pituitary in homozygous betathalassemia: MRI evaluation and correlation with gonadal function. J. Pediatr. Endocrinol. Metab. 13: 179-184.
15. Riggs,B.L., S.Khosla&L.J.Melton III. 1998.Aunitarymodel for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13: 763-773.
16. Geusens, P.P. & S. Boonen. 2002. Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm. Res. 58(Suppl. 3): 49-55.
17. Rucker, D., S. Ezzat, A. Diamandi, et al. 2004. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin. Endocrinol. 60: 491-499.
18. Soliman, A.T., N. El Banna, M. Abdel Fattah, et al. 1998. Bone mineral density in prepubertal children with betathalassemia: correlation with growth and hormonal data. Metabolism 47: 541-548.
19. Morabito, N., A. Gaudio, A. Lasco, et al. 2004. Osteoprotegerin and RANKL in the pathogenesis of thalassemiainduced osteoporosis:newpieces of the puzzle. J.BoneMiner. Res. 19: 722-727.
20. Mahachoklertwattana, P., V. Srikulchayanonta, A. Chuansumrit, et al. 2003. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J. Clin. Endocrinol. Metab. 88: 3966-3972.
21. DeSanctis,V.,A.Pinamonti, A. DiPalma, et al. 1996.Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur. J. Pediatr. 155: 368-372.
22. Ma, E.S., K.K. Lam, A.Y. Chan, et al. 2003. Transferrin receptor-2 polymorphisms and iron overload in transfusion independent-thalassemia intermedia. Haematologica 88: 345-346 [letter].
23. Michelson, J. & A. Cohen. 1988. Incidence and treatment of fractures in thalassemia. J. Orthop. Trauma 2: 29-32.
24. Voskaridou, E., M.C. Kyrtsonis, E. Terpos, et al. 2001. Bone resorption is increased in young adults with thalassaemia major. Br. J. Haematol. 112: 36-41.
25. Voskaridou, E., E. Terpos, G. Spina, et al. 2003. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br. J. Haematol. 123: 730-737.
26. Dresner Pollack, R., E. Rachmilewitz, A. Blumenfeld, et al. 2000. Bone mineral metabolism in adults with betathalassaemia major and intermedia. Br. J. Haematol. 111: 902-907.
27. Voskaridou, E. & E. Terpos. 2005. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur. J. Haematol. 74: 359-361.
28. Voskaridou, E., A. Anagnostopoulos, K. Konstantopoulos, et al. 2006. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a singlecenter, randomized, placebo-controlled trial. Haematologica 91: 1193-1202.
29. Morabito,N., G.T. Russo, A.Gaudio, et al. 2007. The "lively" cytokines network in beta-ThalassemiaMajor-related osteoporosis. Bone 40: 1588-1594.
30. Domrongkitchaiporn, S., V. Sirikulchayanonta, P. Angchaisuksiri, et al. 2003. Abnormalities in bone mineral density and bone histology in thalassemia. J. Bone Miner. Res. 18: 1682-1688.
31. Voskaridou, E.,D. Christoulas, C. Xirakia, et al. 2009. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94: 725-728.
32. Lindsay, R. 1993. Prevention and treatment of osteoporosis. Lancet 341: 801-805.
33. Anapliotou, M.L., I.T. Kastanias, P. Psara, et al. 1995. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin. Endocrinol. 42: 279-287.
34. Canatan,D.,N.Akar&A.Arcasoy. 1995. Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol. 93: 20-24.
35. Angastiniotis, M.,N. Pavlides, K. Aristidou, et al. 1998. Bone pain in thalassaemia: assessment ofDEXAandMRIfindings. J. Pediatr. Endocrinol. Metab. 11(Suppl. 3): 779-784.
36. Kosaryan, M., M.F. Zadeh & V.K. Shahi. 2004. The bone density of thalassemic patients of Boo Ali Sina hospital, Sari, Iran in 2002; does hydroxyurea help? Pediatr. Endocrinol. Rev. 2(Suppl. 2): 303-306.
37. Morabito, N., A. Lasco, A. Gaudio, et al. 2002. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos. Int. 13: 644-649.
38. Pennisi, P., G. Pizzarelli, M. Spina, et al. 2003. Quantitative ultrasound of bone and clodronate effects in thalassemiainduced osteoporosis. J. Bone Miner. Metab. 21: 402-408.
39. Voskaridou, E., D. Christoulas, M. Konstantinidou, et al. 2008. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long termfollow up a randomized, placebo-controlled trial. Haematologica 93: 1588-1590.
40. Voskaridou, E., D. Christoulas, E. Antoniadou & E. Terpos. 2008. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia induced osteoporosis. Acta Haematol. 119: 40-44.